Aspirin for secondary prevention of venous thromboembolism. WARFASA: far from being conclusive

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:La revue de medecine interne Jg. 34; H. 2; S. 69
Hauptverfasser: Delluc, A, Lacut, K, Mottier, D
Format: Journal Article
Sprache:Französisch
Veröffentlicht: France Elsevier 01.02.2013
Schlagworte:
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Aspirin - administration & dosage
Aspirin - adverse effects
Aspirin - therapeutic use
Hemorrhage - epidemiology
Hemorrhage - etiology
Hemorrhage - prevention & control
Human health and pathology
Humans
Life Sciences
Pulmonary Embolism - chemically induced
Pulmonary Embolism - epidemiology
Pulmonary Embolism - etiology
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Secondary Prevention - methods
Venous Thromboembolism - complications
Venous Thromboembolism - drug therapy
Venous Thromboembolism - epidemiology
Venous Thromboembolism - prevention & control
Warfarin - administration & dosage
Warfarin - adverse effects
Warfarin - therapeutic use
ISSN:1768-3122, 0248-8663, 1768-3122
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Bibliographie:SourceType-Scholarly Journals-1
ObjectType-Review-3
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1768-3122
0248-8663
1768-3122
DOI:10.1016/j.revmed.2012.10.363